| Year |
Citation |
Score |
| 2023 |
Bannoura SF, Aboukameel A, Khan HY, Uddin MH, Jang H, Beal E, Thangasamy A, Kim S, Wagner KU, Mohammad R, Al-Hallak MN, Pasche BC, Azmi AS. Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis. Biorxiv : the Preprint Server For Biology. PMID 38187605 DOI: 10.1101/2023.12.18.572102 |
0.35 |
|
| 2023 |
Uddin MH, Al-Hallak MN, Khan HY, Aboukameel A, Li Y, Bannoura SF, Dyson G, Kim S, Mzannar Y, Azar I, Odisho T, Mohamed A, Landesman Y, Kim S, Beydoun R, ... Mohammad RM, et al. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Clinical and Translational Medicine. 13: e1513. PMID 38131168 DOI: 10.1002/ctm2.1513 |
0.311 |
|
| 2023 |
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal EW, Tobon M, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, ... ... Mohammad RM, et al. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. Molecular Cancer Therapeutics. PMID 37703579 DOI: 10.1158/1535-7163.MCT-23-0251 |
0.401 |
|
| 2023 |
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal E, Tobon M, Kim S, Beydoun R, Baloglu E, Senapedis W, El-Rayes B, ... ... Mohammad RM, et al. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. Biorxiv : the Preprint Server For Biology. PMID 37034616 DOI: 10.1101/2023.03.27.534309 |
0.365 |
|
| 2022 |
Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, ... Mohammad RM, et al. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. Cancer Research Communications. 2: 342-352. PMID 35573474 DOI: 10.1158/2767-9764.crc-21-0176 |
0.406 |
|
| 2021 |
Khan HY, Uddin MH, Balasubramanian SK, Sulaiman N, Iqbal M, Chaker M, Aboukameel A, Li Y, Senapedis W, Baloglu E, Mohammad RM, Zonder J, Azmi AS. PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma. Cancers. 14. PMID 35008323 DOI: 10.3390/cancers14010160 |
0.413 |
|
| 2021 |
Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, ... Mohammad RM, et al. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Molecular Cancer Therapeutics. PMID 34253597 DOI: 10.1158/1535-7163.MCT-20-1105 |
0.321 |
|
| 2021 |
Balasubramanian SK, Khan H, Uddin MH, Aboukameel A, Li Y, Zonder JA, Senapedis WT, Baloglu E, Mohammad R, Shah JJ, Landesman Y, Shacham S, Kauffman MG, Azmi AS. Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma Blood. 138: 683-683. DOI: 10.1182/blood-2021-145615 |
0.396 |
|
| 2020 |
Khan HY, Mpilla GB, Sexton R, Viswanadha S, Penmetsa KV, Aboukameel A, Diab M, Kamgar M, Al-Hallak MN, Szlaczky M, Tesfaye A, Kim S, Philip PA, Mohammad RM, Azmi AS. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Cancers. 12. PMID 32235707 DOI: 10.3390/Cancers12030750 |
0.403 |
|
| 2019 |
Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y, Mohammad RM, Azmi AS, Sukari A. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. International Journal of Molecular Sciences. 21. PMID 31905765 DOI: 10.3390/Ijms21010237 |
0.452 |
|
| 2019 |
Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, et al. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. Cancers. 11. PMID 31795447 DOI: 10.3390/Cancers11121902 |
0.474 |
|
| 2019 |
Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model. Heliyon. 5: e02290. PMID 31508518 DOI: 10.1016/J.Heliyon.2019.E02290 |
0.496 |
|
| 2019 |
Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM. DNA-Methylation-Caused Downregulation of Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. Cancers. 11. PMID 31382411 DOI: 10.3390/Cancers11081101 |
0.455 |
|
| 2019 |
Siveen KS, Prabhu KS, Parray AS, Merhi M, Arredouani A, Chikri M, Uddin S, Dermime S, Mohammad RM, Steinhoff M, Janahi IA, Azizi F. Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation. Scientific Reports. 9: 1554. PMID 30733502 DOI: 10.1038/S41598-018-37469-8 |
0.374 |
|
| 2019 |
Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple negative breast cancer stem cells. Molecular Oncology. PMID 30636104 DOI: 10.1002/1878-0261.12444 |
0.35 |
|
| 2019 |
Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A. Abstract 3680: SRSF2-dependent MBD2v2 expression is induced by obesity and promotes tumor-initiating triple negative breast cancer stem cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3680 |
0.336 |
|
| 2019 |
Azmi AS, Landesman Y, Kauffman M, Shacham S, Mpilla G, Aboukameel A, Kim S, Kamgar M, Tesfaye A, Mohammad RM, Philip PA. Abstract 3476: Evaluable antitumor activity in metastatic pancreatic adenocarcinoma with specific inhibitor of nuclear export based treatment Cancer Research. 79: 3476-3476. DOI: 10.1158/1538-7445.Am2019-3476 |
0.493 |
|
| 2019 |
Muqbil I, Sexton R, Mpilla G, Tesfaye A, Kim S, Philip PA, Aboukameel A, Viswanadah S, Penmesta KV, Mohammad RM, Azmi AS. Abstract 3069: Efficacy of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor, in preclinical models of gastrointestinal cancers Cancer Research. 79: 3069-3069. DOI: 10.1158/1538-7445.Am2019-3069 |
0.412 |
|
| 2018 |
Diab M, Azmi A, Mohammad R, Philip PA. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opinion On Pharmacotherapy. 1-12. PMID 30592647 DOI: 10.1080/14656566.2018.1561869 |
0.343 |
|
| 2018 |
Krishnankutty R, Iskandarani A, Therachiyil L, Uddin S, Azizi F, Kulinski M, Bhat AA, Mohammad RM. Anticancer Activity of Camel Milk via Induction of Autophagic Death in Human Colorectal and Breast Cancer Cells Asian Pacific Journal of Cancer Prevention : Apjcp. 19: 3501-3509. PMID 30583676 DOI: 10.31557/Apjcp.2018.19.12.3501 |
0.425 |
|
| 2018 |
Imperial R, Ahmed Z, Toor OM, Erdoğan C, Khaliq A, Case P, Case J, Kennedy K, Cummings LS, Melton N, Raza S, Diri B, Mohammad R, El-Rayes B, Pluard T, et al. Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. Molecular Cancer. 17: 177. PMID 30577807 DOI: 10.1186/S12943-018-0923-9 |
0.338 |
|
| 2018 |
Muqbil I, Azmi AS, Mohammad RM. Nuclear Export Inhibition for Pancreatic Cancer Therapy. Cancers. 10. PMID 29735942 DOI: 10.3390/Cancers10050138 |
0.405 |
|
| 2018 |
Nair K, Iskandarani A, Al-Thani R, Mohammad R, Jaoua S. The Replacement of five Consecutive Amino Acids in the Cyt1A Protein of Bacillus thuringiensis Enhances its Cytotoxic Activity against Lung Epithelial Cancer Cells. Toxins. 10. PMID 29547530 DOI: 10.3390/Toxins10030125 |
0.394 |
|
| 2018 |
Mpilla G, Muqbil I, Aboukameel A, Philip PA, Senapedis W, Baloglu E, Landesman Y, Kauffman M, Shacham S, Mohammad RM, Azmi AS. Abstract 4368: PAK4-NAMPT dual inhibition as a feasible strategy for treatment of resistant pancreatic neuroendocrine tumors Cancer Research. 78: 4368-4368. DOI: 10.1158/1538-7445.Am2018-4368 |
0.504 |
|
| 2018 |
Muqbil I, Mahdi Z, Choudhary R, Baloglu E, Senapedis W, Landesman Y, Shacham S, Kauffman M, Kim S, Beydoun R, Berri RN, Shields A, Mohammad RM, Azmi AS. Abstract 2491: Nuclear exporter protein XPO1 a novel prognostic and therapeutic target in gastric cancer Cancer Research. 78: 2491-2491. DOI: 10.1158/1538-7445.Am2018-2491 |
0.371 |
|
| 2017 |
Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget. 8: 82144-82155. PMID 29137251 DOI: 10.18632/Oncotarget.19285 |
0.368 |
|
| 2017 |
Prabhu KS, Siveen KS, Kuttikrishnan S, Iskandarani A, Tsakou M, Achkar IW, Therachiyil L, Krishnankutty R, Parray A, Kulinski M, Merhi M, Dermime S, Mohammad RM, Uddin S. Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells. Plos One. 12: e0180895. PMID 28704451 DOI: 10.1371/Journal.Pone.0180895 |
0.484 |
|
| 2017 |
Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. Small Gtpases. 0. PMID 28641032 DOI: 10.1080/21541248.2017.1329694 |
0.343 |
|
| 2017 |
Achkar IW, Mraiche F, Mohammad RM, Uddin S. Anticancer potential of sanguinarine for various human malignancies. Future Medicinal Chemistry. PMID 28636454 DOI: 10.4155/Fmc-2017-0041 |
0.507 |
|
| 2017 |
Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. PMID 28574828 DOI: 10.18632/Oncotarget.17869 |
0.49 |
|
| 2017 |
Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Scientific Reports. 7: 44125. PMID 28281569 DOI: 10.1038/Srep44125 |
0.438 |
|
| 2017 |
Bhat AA, Prabhu KS, Kuttikrishnan S, Krishnankutty R, Babu J, Mohammad RM, Uddin S. Potential therapeutic targets of Guggulsterone in cancer. Nutrition & Metabolism. 14: 23. PMID 28261317 DOI: 10.1186/S12986-017-0180-8 |
0.409 |
|
| 2017 |
Siveen KS, Uddin S, Mohammad RM. Targeting acute myeloid leukemia stem cell signaling by natural products. Molecular Cancer. 16: 13. PMID 28137265 DOI: 10.1186/S12943-016-0571-X |
0.351 |
|
| 2017 |
Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 16: 76-87. PMID 28062705 DOI: 10.1158/1535-7163.Mct-16-0205 |
0.504 |
|
| 2017 |
Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, Dermime S, Mohammad RM, Uddin S. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges. Current Vascular Pharmacology. PMID 28056756 DOI: 10.2174/1570161115666170105124038 |
0.301 |
|
| 2017 |
Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Kauffman M, Shacham S, Philip PA, Mohammad RM. Abstract 464: Novel role of xpo1 in regulating MicroRNAs related to pancreatic ductal adenocarcinoma invasion and metastasis Cancer Research. 77: 464-464. DOI: 10.1158/1538-7445.Am2017-464 |
0.332 |
|
| 2017 |
Azmi AS, Aboukameel A, Muqbil I, Li Y, Senapedis W, Baloglu E, Landesman Y, Kauffman M, Shacham S, Al-Katib A, Mohammad RM. Abstract 1358: p21 activated kinase 4 (pak4) as a novel therapeutic target for non-hodgkin's lymphoma Cancer Research. 77: 1358-1358. DOI: 10.1158/1538-7445.Am2017-1358 |
0.329 |
|
| 2016 |
Azmi AS, Mohammad RM. Targeting Cancer at the Nuclear Pore. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4180-4182. PMID 27863200 DOI: 10.1200/Jco.2016.67.5637 |
0.308 |
|
| 2016 |
Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. PMID 27713151 DOI: 10.18632/Oncotarget.12428 |
0.45 |
|
| 2016 |
Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Letters. PMID 27693556 DOI: 10.1016/J.Canlet.2016.09.016 |
0.438 |
|
| 2016 |
Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. Journal of Clinical Medicine. 5. PMID 27322337 DOI: 10.3390/Jcm5060059 |
0.311 |
|
| 2016 |
Khan OS, Bhat AA, Krishnankutty R, Mohammad RM, Uddin S. Therapeutic Potential of Resveratrol in Lymphoid Malignancies. Nutrition and Cancer. 68: 365-73. PMID 27028800 DOI: 10.1080/01635581.2016.1152386 |
0.46 |
|
| 2016 |
Iskandarani A, Bhat AA, Siveen KS, Prabhu KS, Kuttikrishnan S, Khan MA, Krishnankutty R, Kulinski M, Nasr RR, Mohammad RM, Uddin S. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. Journal of Translational Medicine. 14: 69. PMID 26956626 DOI: 10.1186/S12967-016-0823-Y |
0.519 |
|
| 2016 |
Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M, Mohammad RM. Involvement of F-BOX proteins in progression and development of human malignancies. Seminars in Cancer Biology. 36: 18-32. PMID 26410033 DOI: 10.1016/J.Semcancer.2015.09.008 |
0.314 |
|
| 2016 |
Muqbil I, Mohammad RM. Pancreatic cancer immunotherapy: coming of age Translational Cancer Research. 5. DOI: 10.21037/Tcr.2016.10.60 |
0.326 |
|
| 2016 |
Kashyap T, Muqbil I, Aboukameel A, Klebanov B, Mohammad R, Azmi AS, Senapedis W, Shacham S, Kauffman M, Landesman Y. Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo Blood. 128: 4131-4131. DOI: 10.1182/Blood.V128.22.4131.4131 |
0.439 |
|
| 2016 |
Azmi AS, Muqbil I, Aboukameel A, Kauffman M, Shacham S, Mohammad RM, Philip PA. Abstract B38: Clinical translation of nuclear export inhibitor in metastatic pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B38 |
0.351 |
|
| 2015 |
Muqbil I, Mohammad RM. Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome. Annals of Translational Medicine. 3: 312. PMID 26697472 DOI: 10.3978/J.Issn.2305-5839.2015.09.15 |
0.377 |
|
| 2015 |
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, ... ... Mohammad RM, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology. 35: S276-304. PMID 26590477 DOI: 10.1016/J.Semcancer.2015.09.007 |
0.359 |
|
| 2015 |
Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Scientific Reports. 5: 16077. PMID 26536918 DOI: 10.1038/Srep16077 |
0.443 |
|
| 2015 |
Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, et al. Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology. PMID 25936818 DOI: 10.1016/J.Semcancer.2015.03.001 |
0.452 |
|
| 2015 |
Sahin K, Cross B, Sahin N, Ciccone K, Suleiman S, Osunkoya AO, Master V, Harris W, Carthon B, Mohammad R, Bilir B, Wertz K, Moreno CS, Walker CL, Kucuk O. Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model. Archives of Biochemistry and Biophysics. 572: 36-9. PMID 25602702 DOI: 10.1016/J.Abb.2015.01.006 |
0.312 |
|
| 2015 |
Azmi AS, Mohammad RM. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway? Future Medicinal Chemistry. 7: 5-7. PMID 25582328 DOI: 10.4155/Fmc.14.144 |
0.407 |
|
| 2015 |
Sahin K, Orhan C, Tuzcu M, Muqbil I, Sahin N, Gencoglu H, Guler O, Padhye SB, Sarkar FH, Mohammad RM. Erratum to: Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against cisplatin-induced nephrotoxicity. Biological Trace Element Research. 164: 162-3. PMID 25488703 DOI: 10.1007/S12011-014-0198-Y |
0.343 |
|
| 2015 |
Azmi AS, Senapedis W, Baloglu E, Landesman Y, Kauffman M, Shacham S, Wu J, Aboukameel A, Muqbil I, Mohammad RM. Abstract 4688: Overcoming drug resistance and stemness in oncogenic kras driven pancreatic ductal adenocarcinoma through PAK4 inhibition Cancer Research. 75: 4688-4688. DOI: 10.1158/1538-7445.Am2015-4688 |
0.473 |
|
| 2015 |
Azmi AS, Aboukameel A, Carlson RO, Elloul S, Shacham S, Kauffman M, Frenkel R, Mohammad RM. Abstract 1756: Preclinical activity in non-Hodgkin's lymphoma of Selinexor, a selective inhibitor of nuclear export (SINE), is enhanced through combination with standard-of-care therapies Cancer Research. 75: 1756-1756. DOI: 10.1158/1538-7445.Am2015-1756 |
0.506 |
|
| 2015 |
Muqbil I, Aboukameel A, Landesman Y, Kauffman M, Shacham S, Mohammad RM, Azmi AS. Abstract 1424: F-box protein fbxl5 nuclear retention by specific inhibitors of nuclear export induces snail ubiquitination leading to reversal of EMT Cancer Research. 75: 1424-1424. DOI: 10.1158/1538-7445.Am2015-1424 |
0.436 |
|
| 2014 |
Muqbil I, Wu J, Aboukameel A, Mohammad RM, Azmi AS. Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition? Seminars in Cancer Biology. 27: 39-45. PMID 24954011 DOI: 10.1016/J.Semcancer.2014.06.003 |
0.31 |
|
| 2014 |
Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, Mohammad RM. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget. 5: 3444-54. PMID 24899509 DOI: 10.18632/Oncotarget.1813 |
0.478 |
|
| 2014 |
Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, ... ... Mohammad R, et al. Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Cancer Chemotherapy and Pharmacology. 74: 151-66. PMID 24832107 DOI: 10.1007/S00280-014-2476-Y |
0.365 |
|
| 2014 |
Bao B, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Aboukameel A, Mohammad R, Van Buren E, Azmi AS, Sarkar FH. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells and Development. 23: 1947-58. PMID 24734907 DOI: 10.1089/Scd.2013.0551 |
0.402 |
|
| 2014 |
Azmi AS, Mohammad RM. Rectifying cancer drug discovery through network pharmacology. Future Medicinal Chemistry. 6: 529-39. PMID 24649956 DOI: 10.4155/Fmc.14.6 |
0.312 |
|
| 2014 |
Choudhry ZS, Tripathi V, Sutton M, Bao B, Mohammad RM, Azmi AS. Regulation of KRAS-PAK4 axis by microRNAs in cancer. Current Pharmaceutical Design. 20: 5275-8. PMID 24479809 DOI: 10.2174/1381612820666140128203452 |
0.347 |
|
| 2014 |
Sahin K, Orhan C, Tuzcu M, Muqbil I, Sahin N, Gencoglu H, Guler O, Padhye SB, Sarkar FH, Mohammad RM. Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against cisplatin-induced nephrotoxicity. Biological Trace Element Research. 157: 156-63. PMID 24415068 DOI: 10.1007/S12011-014-9886-X |
0.337 |
|
| 2014 |
Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, Nikolovska-Coleska Z. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Molecular Cancer Therapeutics. 13: 565-75. PMID 24019208 DOI: 10.1158/1535-7163.Mct-12-0767 |
0.515 |
|
| 2014 |
Muqbil I, Kauffman M, Shacham S, Mohammad RM, Azmi AS. Understanding XPO1 target networks using systems biology and mathematical modeling. Current Pharmaceutical Design. 20: 56-65. PMID 23530499 DOI: 10.2174/13816128113199990611 |
0.432 |
|
| 2014 |
Azmi AS, Senapedis W, Baloglu E, Landesman Y, Kalid O, Aboukameel A, Bao B, Shacham S, Sarkar FH, Kauffman M, Mohammad RM. Novel PAK4 inhibitors for pancreatic cancer therapy. Journal of Clinical Oncology. 32: 233-233. DOI: 10.1200/Jco.2014.32.3_Suppl.233 |
0.493 |
|
| 2014 |
Azmi AS, Senapedis WT, Landesman Y, Baloglu E, Bao B, Wu J, Ori K, Shacham S, Kauffman M, Mohammad RM. Abstract A24: Novel small molecule PAK4 allosteric modulators show potency against oncogenic K-Ras driven pancreatic cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A24 |
0.383 |
|
| 2014 |
Azmi AS, Shacham S, Kauffman M, McCauley D, Aboukameel A, Mohammad RM. Abstract LB-185: Novel activity of selective inhibitors of nuclear export in epithelial-to-mesenchymal transition models Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-185 |
0.465 |
|
| 2014 |
Azmi AS, Senapedis W, Landesman Y, Baloglu E, Kalid O, Wu J, Bao B, Aboukameel A, Shacham S, Kauffman M, Mohammad RM. Abstract 1771: Novel small molecule pak4 allosteric modulators with activity against pancreatic cancer Cancer Research. 74: 1771-1771. DOI: 10.1158/1538-7445.Am2014-1771 |
0.443 |
|
| 2013 |
Azmi AS, Mohammad RM. Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase". Haematologica. 98: e123. PMID 24006415 DOI: 10.3324/Haematol.2013.095299 |
0.41 |
|
| 2013 |
Azmi AS, Bollig-Fischer A, Bao B, Park BJ, Lee SH, Yong-Song G, Dyson G, Reddy CK, Sarkar FH, Mohammad RM. Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25. Bmc Systems Biology. 7: 85. PMID 24004452 DOI: 10.1186/1752-0509-7-85 |
0.336 |
|
| 2013 |
Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica. 98: 1098-106. PMID 23403316 DOI: 10.3324/Haematol.2012.074781 |
0.429 |
|
| 2013 |
Azmi AS, Bao GW, Gao J, Mohammad RM, Sarkar FH. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced perturbations: a review. Current Drug Discovery Technologies. 10: 147-54. PMID 23237677 DOI: 10.2174/1570163811310020007 |
0.325 |
|
| 2013 |
Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology. 144: 447-56. PMID 23089203 DOI: 10.1053/J.Gastro.2012.10.036 |
0.457 |
|
| 2013 |
Azmi AS, Bollig-Fisher A, Bao B, Joon-Park B, Lee S, Song G, Mohammad RM, Sarkar FH. Abstract 5234: Network interrogations on SNAIL inhibitor GN-25 induced perturbations in HMLE-SNAIL cell line models. Cancer Research. 73: 5234-5234. DOI: 10.1158/1538-7445.Am2013-5234 |
0.451 |
|
| 2013 |
Azmi AS, Bao B, Kauffman M, Shacham S, Mohammad RM. Abstract 3445: Specific inhibitors of nuclear export (SINE) for cancer therapy: from bench to bedside. Cancer Research. 73: 3445-3445. DOI: 10.1158/1538-7445.Am2013-3445 |
0.481 |
|
| 2013 |
Azmi AS, Nikolovka-Coleska Z, Abidi M, Marsack K, Masood A, Yano H, Pregja S, Zonder J, Mohammad RM. Abstract 3438: Selective inhibitors of Mcl-1 with potent activity against multiple myeloma patient cells and animal xenografts. Cancer Research. 73: 3438-3438. DOI: 10.1158/1538-7445.Am2013-3438 |
0.542 |
|
| 2013 |
Azmi A, Shacham S, Aboukameel A, Bao B, Kauffman M, Sarkar F, Mohammad R. Targeting nuclear export machinery for pancreatic cancer therapy Pancreatology. 13: e15. DOI: 10.1016/J.Pan.2012.12.106 |
0.32 |
|
| 2012 |
Azmi AS, Kauffman M, McCauley D, Shacham S, Mohammad RM. Novel small-molecule CRM-1 inhibitor for GI cancer therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 245. PMID 27982939 DOI: 10.1200/Jco.2012.30.4_Suppl.245 |
0.39 |
|
| 2012 |
Muqbil I, Bao GW, El-Kharraj R, Shah M, Mohammad RM, Sarkar FH, Azmi AS. Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy. Journal of Stem Cell Research & Therapy. PMID 24319631 DOI: 10.4172/2157-7633.S7-005 |
0.393 |
|
| 2012 |
Alian OM, Azmi AS, Mohammad RM. Network insights on oxaliplatin anti-cancer mechanisms. Clinical and Translational Medicine. 1: 26. PMID 23369220 DOI: 10.1186/2001-1326-1-26 |
0.331 |
|
| 2012 |
Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. Plos One. 7: e52095. PMID 23251689 DOI: 10.1371/Journal.Pone.0052095 |
0.478 |
|
| 2012 |
Haq S, Ali S, Mohammad R, Sarkar FH. The complexities of epidemiology and prevention of gastrointestinal cancers. International Journal of Molecular Sciences. 13: 12556-72. PMID 23202913 DOI: 10.3390/Ijms131012556 |
0.306 |
|
| 2012 |
Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. Journal of Hematology & Oncology. 5: 57. PMID 22989009 DOI: 10.1186/1756-8722-5-57 |
0.407 |
|
| 2012 |
Ulu R, Dogukan A, Tuzcu M, Gencoglu H, Ulas M, Ilhan N, Muqbil I, Mohammad RM, Kucuk O, Sahin K. Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 50: 1675-9. PMID 22414646 DOI: 10.1016/J.Fct.2012.02.082 |
0.301 |
|
| 2012 |
Muqbil I, Beck FW, Bao B, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS. Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol. Current Pharmaceutical Design. 18: 1645-54. PMID 22288443 DOI: 10.2174/138161212799958567 |
0.382 |
|
| 2012 |
Shamim U, Hanif S, Albanyan A, Beck FW, Bao B, Wang Z, Banerjee S, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. Journal of Cellular Physiology. 227: 1493-500. PMID 21678400 DOI: 10.1002/Jcp.22865 |
0.393 |
|
| 2012 |
Azmi AS, Mohammad RM, Sarkar FH. Abstract A1: SNAIL inhibitor GN-25 induces MET through Global Reprograming of EMT Network Genes: a Systems and Network Analysis Cancer Research. 72. DOI: 10.1158/1538-7445.Csb12-A1 |
0.356 |
|
| 2012 |
Bajwa N, Abulwerdi F, Liao C, Mady A, Bernardo JD, Azmi A, Cierpicki T, Stuckey J, Showalter H, Mohammad R, Nikolovska-Coleska Z. Abstract 2917: Design, synthesis and biological evaluation of two chemical classes as novel small molecule Mcl-1 inhibitors Cancer Research. 72: 2917-2917. DOI: 10.1158/1538-7445.Am2012-2917 |
0.452 |
|
| 2012 |
Rodrigueza WV, Whitehead C, Mohammad R, McGovern JP, Wick MJ, Rasco D, Tolcher AW, Bisgaier CL. Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft Cancer Research. 72: 2764-2764. DOI: 10.1158/1538-7445.Am2012-2764 |
0.398 |
|
| 2012 |
Azmi AS, Shacham S, McCauley D, Kauffman M, Mohammad RM. Abstract 1825: Novel small molecule CRM-1 inhibitor for Non Hodgkin's Lymphoma Cancer Research. 72: 1825-1825. DOI: 10.1158/1538-7445.Am2012-1825 |
0.458 |
|
| 2012 |
Azmi AS, McCauley D, Shacham S, Kauffman M, Mohammad RM. Abstract 1815: CRM-1 as a potential therapeutic target in pancreatic cancer Cancer Research. 72: 1815-1815. DOI: 10.1158/1538-7445.Am2012-1815 |
0.525 |
|
| 2012 |
Cross B, Sahin K, Sahin N, Ciccone K, Osunkoya A, Master V, Harris W, Carthon B, Mohammad R, Bilir B, Canter D, Wertz K, Wu D, Moreno C, Walker C, et al. 152 Lycopene In The Prevention Of Renal Cell Cancer In The Tsc2 Mutant Eker Rat Model The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.202 |
0.302 |
|
| 2011 |
Muqbil I, Masood A, Sarkar FH, Mohammad RM, Azmi AS. Progress in nanotechnology based approaches to enhance the potential of chemopreventive agents. Cancers. 3: 428-45. PMID 24212623 DOI: 10.3390/Cancers3010428 |
0.324 |
|
| 2011 |
Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. American Journal of Translational Research. 3: 374-82. PMID 21904657 |
0.371 |
|
| 2011 |
Masood A, Azmi AS, Mohammad RM. Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy. Cancers. 3: 1527-49. PMID 21760983 DOI: 10.3390/Cancers3021527 |
0.42 |
|
| 2011 |
Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2: 378-92. PMID 21623005 DOI: 10.18632/Oncotarget.269 |
0.418 |
|
| 2011 |
Azmi AS, Beck FW, Sarkar FH, Mohammad RM. Network perspectives on HDM2 inhibitor chemotherapy combinations. Current Pharmaceutical Design. 17: 640-52. PMID 21391913 DOI: 10.2174/138161211795222612 |
0.387 |
|
| 2011 |
Azmi AS, Philip PA, Beck FWJ, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH, Mohammad RM. MI-219-zinc combination: A new paradigm in MDM2 inhibitor-based therapy Oncogene. 30: 117-126. PMID 20818437 DOI: 10.1038/Onc.2010.403 |
0.363 |
|
| 2011 |
Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opinion On Emerging Drugs. 16: 59-70. PMID 20812891 DOI: 10.1517/14728214.2010.515210 |
0.429 |
|
| 2011 |
Levi E, Zhang L, Aboukameel A, Rishi S, Mohammad RM, Polin L, Hatfield JS, Rishi AK. Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor. Cancer Chemotherapy and Pharmacology. 67: 1401-13. PMID 20809119 DOI: 10.1007/S00280-010-1442-6 |
0.466 |
|
| 2011 |
Azmi AS, Al-Katib A, Aboukameel A, Kauffman M, McCauley D, Mohammad R, Shacham S. Development of a Novel Small Molecule CRM-1 Inhibitor for Non Hodgkin's Lymphoma Blood. 118: 598-598. DOI: 10.1182/Blood.V118.21.598.598 |
0.45 |
|
| 2011 |
Sosin AM, Yang D, Mohammad RM, Al-Katib A. Abstract 594: MDM2 inhibition by MI-219 elicits differential molecular effects in wild-type p53 lymphoma cells Cancer Research. 71: 594-594. DOI: 10.1158/1538-7445.Am2011-594 |
0.441 |
|
| 2011 |
Azmi AS, Philip PA, Choi M, Shields AF, Sarkar FH, Mohammad RM. Abstract 4910: Unveiling the role of network and systems biology in pancreatic cancer drug discovery Cancer Research. 71: 4910-4910. DOI: 10.1158/1538-7445.Am2011-4910 |
0.426 |
|
| 2011 |
Azmi AS, Padhye S, Banerjee S, Aboukameel A, Sarkar FH, Mohammad RM. Abstract 3706: Novel analogs of dietary thymoquinone with superior bioavailability and anti-tumor activity against GI cancers Cancer Research. 71: 3706-3706. DOI: 10.1158/1538-7445.Am2011-3706 |
0.467 |
|
| 2011 |
Abulwerdi F, Azmi A, Liu M, Aboukameel A, Liao C, Stuckey J, Cierpicki T, Mohammad RM, Nikolovska-Coleska Z. Abstract 2822: Targeting Mcl-1 regulated apoptosis pathway as a novel therapy in pancreatic cancer Cancer Research. 71: 2822-2822. DOI: 10.1158/1538-7445.Am2011-2822 |
0.546 |
|
| 2011 |
Azmi AS, Park B, Mohammad RM. Abstract 2585: Snail-p53 interaction inhibitor GN25 and its combination with Oxaliplatin targets both hedgehog signaling and K-ras pathway in pancreatic cancer Cancer Research. 71: 2585-2585. DOI: 10.1158/1538-7445.Am2011-2585 |
0.365 |
|
| 2011 |
Wang Z, Banerjee S, Ahmad A, Azmi AS, Bao B, Ali S, Mohammad RM, Miele L, Korc M, Sarkar FH. Abstract 2385: Activated Kras and INK4a/Arf deficiency cooperate to produce pancreatic cancer involved with Notch and NF-κB pathways Cancer Research. 71: 2385-2385. DOI: 10.1158/1538-7445.Am2011-2385 |
0.362 |
|
| 2011 |
Azmi AS, Sukari A, Philip PA, Mohammad RM. Abstract 209: Zinc is essential for the efficacy of p53 reactivating drugs Cancer Research. 71: 209-209. DOI: 10.1158/1538-7445.Am2011-209 |
0.412 |
|
| 2010 |
Farhana L, Dawson MI, Xia Z, Aboukameel A, Xu L, Liu G, Das JK, Hatfield J, Levi E, Mohammad R, Fontana JA. Adamantyl-substituted retinoid-related molecules induce apoptosis in human acute myelogenous leukemia cells. Molecular Cancer Therapeutics. 9: 2903-13. PMID 21062916 DOI: 10.1158/1535-7163.Mct-10-0546 |
0.485 |
|
| 2010 |
Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Molecular Cancer Therapeutics. 9: 3137-44. PMID 21041384 DOI: 10.1158/1535-7163.Mct-10-0642 |
0.354 |
|
| 2010 |
Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, Sarkar FH, Mohammad RM. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutrition and Cancer. 62: 938-46. PMID 20924969 DOI: 10.1080/01635581.2010.509832 |
0.496 |
|
| 2010 |
Al-Katib A, Arnold AA, Aboukameel A, Sosin A, Smith P, Mohamed AN, Beck FW, Mohammad RM. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. Molecular Cancer. 9: 228. PMID 20809973 DOI: 10.1186/1476-4598-9-228 |
0.776 |
|
| 2010 |
Nautiyal J, Yu Y, Aboukameel A, Kanwar SS, Das JK, Du J, Patel BB, Sarkar FH, Rishi AK, Mohammad RM, Majumdar AP. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Molecular Cancer Therapeutics. 9: 1503-14. PMID 20515951 DOI: 10.1158/1535-7163.Mct-10-0019 |
0.44 |
|
| 2010 |
Azmi AS, Philip PA, Zafar SF, Sarkar FH, Mohammad RM. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opinion On Therapeutic Targets. 14: 611-20. PMID 20426700 DOI: 10.1517/14728222.2010.487066 |
0.385 |
|
| 2010 |
Banerjee S, Azmi AS, Padhye S, Singh MW, Baruah JB, Philip PA, Sarkar FH, Mohammad RM. Structure-activity studies on therapeutic potential of thymoquinone analogs in pancreatic cancer Pharmaceutical Research. 27: 1146-1158. PMID 20422266 DOI: 10.1007/S11095-010-0145-3 |
0.466 |
|
| 2010 |
Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Reviews in Medicinal Chemistry. 10: 518-26. PMID 20377522 DOI: 10.2174/138955710791384054 |
0.411 |
|
| 2010 |
Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Current Cancer Drug Targets. 10: 319-31. PMID 20370686 DOI: 10.2174/156800910791190229 |
0.472 |
|
| 2010 |
Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. European Journal of Cancer (Oxford, England : 1990). 46: 1122-31. PMID 20156675 DOI: 10.1016/J.Ejca.2010.01.015 |
0.426 |
|
| 2010 |
Banerjee S, Choi M, Aboukameel A, Wang Z, Mohammad M, Chen J, Yang D, Sarkar FH, Mohammad RM. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas. 39: 323-31. PMID 19823097 DOI: 10.1097/Mpa.0B013E3181Bb95E7 |
0.448 |
|
| 2010 |
Nautiyal J, Yu Y, Aboukameel A, Kanwar SS, Das JK, Sarkar FH, Rishi AK, Mohammad R, Patel BB, Majumdar A. Abstract 5406: ErbB inhibitory protein [EBIP], a modified ectodomain of EGFR, synergizes with dasatinib to inhibit growth of breast cancer cells Cancer Research. 70: 5406-5406. DOI: 10.1158/1538-7445.Am10-5406 |
0.428 |
|
| 2010 |
Azmi AS, Philip PA, Aboukameel A, Banerjee S, Wang Z, Wang S, Yang D, Sarkar FH, Mohammad RM. Abstract 4535: MDM2 inhibitor MI-319 in combination with cisplatin/oxaliplatin is an effective treatment for pancreatic cancer independent of p53 function Cancer Research. 70: 4535-4535. DOI: 10.1158/1538-7445.Am10-4535 |
0.427 |
|
| 2010 |
Sosin AM, Burger AM, Yang D, Mohammad RM, Al-Katib A. Abstract 4516: A new class of MDM2 inhibitors cause growth inhibition and stabilize wt p53 in lymphoma cells but do not interfere with MDM2 E3 ligase activity Cancer Research. 70: 4516-4516. DOI: 10.1158/1538-7445.Am10-4516 |
0.421 |
|
| 2010 |
Azmi AS, Sarkar FH, Mohammad RM. Abstract A36: Systems biology: Implications in assessing drug-drug interactions in pancreatic cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-A36 |
0.395 |
|
| 2009 |
Tageja N, Padheye S, Dandawate P, Al-Katib A, Mohammad RM. New targets for the treatment of follicular lymphoma. Journal of Hematology & Oncology. 2: 50. PMID 20030851 DOI: 10.1186/1756-8722-2-50 |
0.31 |
|
| 2009 |
Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Molecular Cancer. 8: 115. PMID 19958544 DOI: 10.1186/1476-4598-8-115 |
0.442 |
|
| 2009 |
Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Research. 69: 5575-83. PMID 19549912 DOI: 10.1158/0008-5472.Can-08-4235 |
0.469 |
|
| 2009 |
Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4038-45. PMID 19509168 DOI: 10.1158/1078-0432.Ccr-08-2808 |
0.31 |
|
| 2009 |
Nazeem S, Azmi AS, Hanif S, Ahmad A, Mohammad RM, Hadi SM, Kumar KS. Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis. 24: 413-8. PMID 19505895 DOI: 10.1093/Mutage/Gep023 |
0.48 |
|
| 2009 |
Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, Mohammad RM. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Research. 69: 2757-65. PMID 19318573 DOI: 10.1158/0008-5472.Can-08-3060 |
0.54 |
|
| 2009 |
Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, Mohammad RM. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. Journal of Hematology & Oncology. 2: 8. PMID 19220884 DOI: 10.1186/1756-8722-2-8 |
0.489 |
|
| 2009 |
Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. Journal of Cellular Physiology. 218: 13-21. PMID 18767026 DOI: 10.1002/Jcp.21567 |
0.484 |
|
| 2008 |
Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Molecular Cancer Therapeutics. 7: 2884-93. PMID 18790769 DOI: 10.1158/1535-7163.Mct-08-0438 |
0.492 |
|
| 2008 |
Sun Y, Wu J, Aboukameel A, Banerjee S, Arnold AA, Chen J, Nikolovska-Coleska Z, Lin Y, Ling X, Yang D, Wang S, Al-Katib A, Mohammad RM. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biology & Therapy. 7: 1418-26. PMID 18769131 DOI: 10.4161/Cbt.7.9.6430 |
0.785 |
|
| 2008 |
Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S, Kong D, Wang S, Sarkar FH, Mohammad RM. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. International Journal of Cancer. Journal International Du Cancer. 123: 958-66. PMID 18528859 DOI: 10.1002/Ijc.23610 |
0.51 |
|
| 2008 |
Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharmaceutical Research. 25: 2117-24. PMID 18427961 DOI: 10.1007/S11095-008-9581-8 |
0.39 |
|
| 2008 |
Banerjee S, Wang Z, Mohammad M, Sarkar FH, Mohammad RM. Efficacy of selected natural products as therapeutic agents against cancer. Journal of Natural Products. 71: 492-6. PMID 18302335 DOI: 10.1021/Np0705716 |
0.332 |
|
| 2008 |
Mohammad R, Giri A, Goustin AS. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. Recent Patents On Anti-Cancer Drug Discovery. 3: 20-30. PMID 18289121 DOI: 10.2174/157489208783478676 |
0.482 |
|
| 2008 |
Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, Mohammad RM. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Molecular Cancer. 7: 20. PMID 18275607 DOI: 10.1186/1476-4598-7-20 |
0.786 |
|
| 2008 |
Wang Z, Azmi AS, Banerjee S, Aboukameel A, Wang S, Sarkar FH, Mohammad RM. TW-37 INHIBITS CELL GROWTH AND INDUCES APOPTOSIS IN PANCREATIC CANCER Pancreas. 37: 500. DOI: 10.1097/01.Mpa.0000335408.77670.4A |
0.472 |
|
| 2008 |
Banerjee S, Kaseb A, Wang Z, Kong D, Padhaye S, Mohammad R, Sarkar FH. IN VIVO MOLECULAR EVIDENCE FOR ENHANCED CHEMOSENSITIVITY OF PANCREATIC CANCER CELLS TO GEMCITABINE AND OXALIPLATIN BY THYMOQUINONE Pancreas. 37: 461. DOI: 10.1097/01.Mpa.0000335341.28085.C8 |
0.392 |
|
| 2007 |
Zhang L, Levi E, Majumder P, Yu Y, Aboukameel A, Du J, Xu H, Mohammad R, Hatfield JS, Wali A, Adsay V, Majumdar AP, Rishi AK. Transactivator of transcription-tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo. Molecular Cancer Therapeutics. 6: 1661-72. PMID 17513614 DOI: 10.1158/1535-7163.Mct-06-0653 |
0.42 |
|
| 2007 |
Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2226-35. PMID 17404107 DOI: 10.1158/1078-0432.Ccr-06-1574 |
0.453 |
|
| 2007 |
Zhang M, Ling Y, Yang CY, Liu H, Wang R, Wu X, Ding K, Zhu F, Griffith BN, Mohammad RM, Wang S, Yang D. A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. Annals of Hematology. 86: 471-81. PMID 17396262 DOI: 10.1007/S00277-007-0288-4 |
0.446 |
|
| 2007 |
Mohammad RM, Sun Y, Wang S, Aboukameel A, Al-Katib AM. Evaluation of TW-37, a pan Bcl-2 Proteins Small-Molecule Inhibitor, Against Spectrum of Human B-Cell Lines and Patient-Derived Samples. Blood. 110: 4521-4521. DOI: 10.1182/Blood.V110.11.4521.4521 |
0.425 |
|
| 2007 |
Aboukameel A, Goustin A, Mohammad R, Zuany-Amorim C, Bissery M, Al-Katib AM. Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin’s Xenograft Animal Models: Preclinical Evaluation. Blood. 110: 2339-2339. DOI: 10.1182/Blood.V110.11.2339.2339 |
0.364 |
|
| 2007 |
Wang Z, Song W, Aboukameel A, Wang G, Wang S, Sarkar FH, Mohammad RM. TW-37, A NONPEPTIDIC SMALL-MOLECULE INHIBITOR OF BCL-2, INHIBITS INVASION AND ANGIOGENESIS IN PANCREATIC CANCER Pancreas. 35: 434-435. DOI: 10.1097/01.Mpa.0000297810.50526.D6 |
0.396 |
|
| 2006 |
Wang Z, Sengupta R, Banerjee S, Li Y, Zhang Y, Rahman KM, Aboukameel A, Mohammad R, Majumdar AP, Abbruzzese JL, Sarkar FH. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Research. 66: 7653-60. PMID 16885366 DOI: 10.1158/0008-5472.Can-06-1019 |
0.49 |
|
| 2006 |
Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer. 106: 1260-8. PMID 16475211 DOI: 10.1002/Cncr.21731 |
0.439 |
|
| 2006 |
Zhang Y, Banerjee S, Wang Z, Xu H, Zhang L, Mohammad R, Aboukameel A, Adsay NV, Che M, Abbruzzese JL, Majumdar AP, Sarkar FH. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Research. 66: 1025-32. PMID 16424038 DOI: 10.1158/0008-5472.Can-05-2968 |
0.447 |
|
| 2006 |
Thoutreddy S, Ali S, Mohammad R, Sarkar FH. Sensitization of pancreatic cancer cells to ApoG2 induced killing by curcumin Journal of Clinical Oncology. 24: 13152-13152. DOI: 10.1200/Jco.2006.24.18_Suppl.13152 |
0.436 |
|
| 2006 |
Thoutreddy S, Mohammad RM, Ali S, Wang S, Sarkar FH. CURCUMIN SENSITIZES PANCREATIC CANCER CELLS TO APOG2 INDUCED KILLING Pancreas. 33: 502. DOI: 10.1097/00006676-200611000-00219 |
0.407 |
|
| 2005 |
Mohammad RM, Wang S, Banerjee S, Wu X, Chen J, Sarkar FH. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas. 31: 317-24. PMID 16258364 DOI: 10.1097/01.Mpa.0000179731.46210.01 |
0.494 |
|
| 2005 |
Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics. 4: 13-21. PMID 15657349 |
0.379 |
|
| 2005 |
Mubarak KK, Pauley RJ, Zhuang Y, Tait L, Aboukameel A, Mohammad RM. Hoxb4-Induced Apoptosis In Reh Cells Is Not Mediated Via The Intrinsic Caspase-9 Pathway Chest. 128: 331. DOI: 10.1378/Chest.128.4_Meetingabstracts.331S |
0.402 |
|
| 2004 |
Ellis KL, Mohammad R, Wang S, Wu X, Chen J, Min J, Sarkar FH. Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3133. PMID 28014863 DOI: 10.1200/Jco.2004.22.14_Suppl.3133 |
0.395 |
|
| 2004 |
Levi E, Mohammad R, Kodali U, Marciniak D, Reddy S, Aboukameel A, Sarkar FH, Kucuk O, Rishi AK, Majumdar AP. EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo. Anticancer Research. 24: 2885-91. PMID 15517892 |
0.321 |
|
| 2004 |
Quiney C, Dauzonne D, Kern C, Fourneron JD, Izard JC, Mohammad RM, Kolb JP, Billard C. Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells. Leukemia Research. 28: 851-61. PMID 15203283 DOI: 10.1016/J.Leukres.2003.12.003 |
0.442 |
|
| 2004 |
Beck FW, Eilender DS, Dandashi MH, Siddiq F, Snell DC, Godmere MA, Al-Katib AM, Mohammad RM. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia. International Journal of Molecular Medicine. 14: 113-9. PMID 15202025 DOI: 10.3892/Ijmm.14.1.113 |
0.382 |
|
| 2004 |
Mensah-Osman E, Al-Katib A, Dandashi M, Mohammad R. XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways. International Journal of Oncology. 23: 1637-44. PMID 14612935 |
0.353 |
|
| 2004 |
Pauley RJ, Zhuang Y, Aboukameel A, Mubarak KK, Tait LR, Mohammad RM. HoxB4 Induces Apoptosis in Acute Lymphoblastic Leukemia Reh Cells Chest. 126. DOI: 10.1378/Chest.126.4_Meetingabstracts.915S |
0.403 |
|
| 2004 |
Ellis K, Mohammad R, Wang S, Wu X, Chen J, Min J, Sarkar FH. Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells Journal of Clinical Oncology. 22: 3133-3133. DOI: 10.1200/jco.2004.22.90140.3133 |
0.387 |
|
| 2004 |
Mohammad R, Wang S, Wu X, Chen J, Min J, Sarkar F. POTENTIATION OF APOPTOSIS INDUCING ACTIVITY OF BL-193, A NONPEPTIDIC SMALL-MOLECULE INHIBITOR OF BCL-2/BCL-XL PROTEINS, BY GENISTEIN IN PANCREATIC CANCER CELLS. Pancreas. 29: 364. DOI: 10.1097/00006676-200411000-00145 |
0.385 |
|
| 2004 |
Mohammad R, Aboukameel A, Kucuk O, Sarkar F. ANTI-TUMOR ACTIVITY OF CISPLATIN IS POTENTIATED BY SOY ISOFLAVONE GENISTEIN IN BXPC-3 PANCREATIC TUMOR XENOGRAFT. Pancreas. 29: 364. DOI: 10.1097/00006676-200411000-00144 |
0.313 |
|
| 2003 |
Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Molecular Cancer Therapeutics. 2: 1361-8. PMID 14707277 |
0.36 |
|
| 2003 |
Zhang Y, Dawson MI, Ning Y, Polin L, Parchment RE, Corbett T, Mohamed AN, Feng KC, Farhana L, Rishi AK, Hogge D, Leid M, Peterson VJ, Zhang XK, Mohammad R, et al. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood. 102: 3743-52. PMID 12893763 DOI: 10.1182/Blood-2003-01-0108 |
0.473 |
|
| 2003 |
Rishi AK, Zhang L, Boyanapalli M, Wali A, Mohammad RM, Yu Y, Fontana JA, Hatfield JS, Dawson MI, Majumdar AP, Reichert U. Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. The Journal of Biological Chemistry. 278: 33422-35. PMID 12816952 DOI: 10.1074/Jbc.M303173200 |
0.446 |
|
| 2003 |
Marciniak DJ, Moragoda L, Mohammad RM, Yu Y, Nagothu KK, Aboukameel A, Sarkar FH, Adsay VN, Rishi AK, Majumdar AP. Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. Gastroenterology. 124: 1337-47. PMID 12730874 DOI: 10.1016/S0016-5085(03)00264-6 |
0.343 |
|
| 2003 |
Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia. Seminars in Oncology. 30: 313-7. PMID 12720160 DOI: 10.1053/Sonc.2003.50043 |
0.36 |
|
| 2003 |
Mensah-Osman E, Al-Katib A, Dandashi M, Mohammad R. XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways. International Journal of Oncology. 23: 1637-1644. DOI: 10.3892/Ijo.23.6.1637 |
0.458 |
|
| 2002 |
Mensah-Osman EJ, Al-Katib AM, Wu HY, Osman NI, Mohammad RM. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity. Molecular Cancer Therapeutics. 1: 1321-6. PMID 12516965 |
0.33 |
|
| 2002 |
Mensah-Osman EJ, Al-Katib AM, Dandashi MH, Mohammad RM. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Molecular Cancer Therapeutics. 1: 1315-20. PMID 12516964 |
0.405 |
|
| 2002 |
Mohammad RM, Aboukameel A, Nabha S, Ibrahim D, Al-Katib A. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient. Journal of Drug Targeting. 10: 405-10. PMID 12442811 DOI: 10.1080/1061186021000001850 |
0.367 |
|
| 2002 |
Zhang Y, Dawson MI, Mohammad R, Rishi AK, Farhana L, Feng KC, Leid M, Peterson V, Zhang XK, Edelstein M, Eilander D, Biggar S, Wall N, Reichert U, Fontana JA. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood. 100: 2917-25. PMID 12351403 DOI: 10.1182/Blood.V100.8.2917 |
0.462 |
|
| 2002 |
Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2735-41. PMID 12171907 |
0.374 |
|
| 2002 |
Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC, Mohammad R, Mossalayi DM, Kolb JP. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. British Journal of Haematology. 117: 842-51. PMID 12060119 DOI: 10.1046/J.1365-2141.2002.03520.X |
0.458 |
|
| 2002 |
Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1277-83. PMID 11948143 |
0.305 |
|
| 2001 |
Wall NR, Beck FWJ, Al-Katib AM, Mohammad RM. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line Journal of Drug Targeting. 9: 329-339. PMID 11770703 DOI: 10.3109/10611860108998769 |
0.481 |
|
| 2001 |
Mohammad RM, Adsay NV, Philip PA, Pettit GR, Vaitkevicius VK, Sarkar FH. Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model Anti-Cancer Drugs. 12: 735-740. PMID 11593055 DOI: 10.1097/00001813-200110000-00005 |
0.38 |
|
| 2001 |
Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. American Journal of Clinical Oncology. 24: 447-52. PMID 11586094 DOI: 10.1097/00000421-200110000-00007 |
0.391 |
|
| 2001 |
Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: Preclinical efficacy Anti-Cancer Drugs. 12: 57-63. PMID 11272287 DOI: 10.1097/00001813-200101000-00008 |
0.388 |
|
| 2000 |
Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM. Effects of Combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines Anti-Cancer Drugs. 11: 385-392. PMID 10912955 DOI: 10.1097/00001813-200006000-00009 |
0.383 |
|
| 2000 |
He Z, Evelhoch JL, Mohammad RM, Adsay NV, Pettit GR, Vaitkevicius VK, Sarkar FH. Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer Pancreas. 21: 69-76. PMID 10881935 DOI: 10.1097/00006676-200007000-00054 |
0.351 |
|
| 2000 |
Beck FW, Al-Katib AM, Ahmad I, Wall NR, Liu KZ, Mantsch HH, Mohammad RM. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells. International Journal of Molecular Medicine. 5: 341-347. PMID 10719048 DOI: 10.3892/Ijmm.5.4.341 |
0.391 |
|
| 2000 |
Wall NR, Mohammad RM, Reddy KB, Al-Katib AM. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh. International Journal of Molecular Medicine. 5: 165-171. PMID 10639596 DOI: 10.3892/Ijmm.5.2.165 |
0.43 |
|
| 1999 |
Wall NR, Mohammad RM, Nabha SM, Pettit GR, Al-Katib AM. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh Biochemical and Biophysical Research Communications. 266: 76-80. PMID 10581168 DOI: 10.1006/Bbrc.1999.1768 |
0.471 |
|
| 1999 |
Wall NR, Mohammad RM, Al-Katib AM. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh Leukemia Research. 23: 881-888. PMID 10573132 DOI: 10.1016/S0145-2126(99)00108-3 |
0.454 |
|
| 1999 |
Aref A, Yudelev M, Mohammad R, Choudhuri R, Orton C, Al-Katib A. Neutron and photon clonogenic survival curves of two chemotherapy resistant human intermediate-grade non-Hodgkin lymphoma cell lines. International Journal of Radiation Oncology, Biology, Physics. 45: 999-1003. PMID 10571208 DOI: 10.1016/S0360-3016(99)00258-8 |
0.347 |
|
| 1999 |
Mohammad RM, Li Y, Mohamed AN, Pettit GR, Adsay V, Vaitkevicius VK, Al-Katib AM, Sarkar FH. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma Pancreas. 19: 353-361. PMID 10547195 DOI: 10.1097/00006676-199911000-00006 |
0.42 |
|
| 1999 |
Liu KZ, Schultz CP, Johnston JB, Beck FW, Al-Katib AM, Mohammad RM, Mantsch HH. Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line. Leukemia. 13: 1273-80. PMID 10450757 DOI: 10.1038/Sj.Leu.2401463 |
0.324 |
|
| 1999 |
Mohammad RM, Limvarapuss C, Wall NR, Hamdy N, Beck FW, Pettit GR, Al-Katib A. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model. International Journal of Oncology. 15: 367-372. PMID 10402249 DOI: 10.3892/Ijo.15.2.367 |
0.477 |
|
| 1999 |
Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FWJ, Wall NR, Al-Katib AM. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine International Journal of Oncology. 14: 945-950. PMID 10200346 DOI: 10.3892/Ijo.14.5.945 |
0.438 |
|
| 1999 |
Li Y, Bhuiyan M, Mohammad RM, Sarkar FH. Induction of apoptosis in breast cancer cells by TPA. Oncogene. 17: 2915-20. PMID 9879997 DOI: 10.1038/Sj.Onc.1202218 |
0.477 |
|
| 1998 |
Wang H, Mohammad RM, Werdell J, Shekhar PV. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. International Journal of Molecular Medicine. 1: 915-23. PMID 9852625 DOI: 10.3892/IJMM.1.6.915 |
0.345 |
|
| 1998 |
Mohammad RM, Beck FW, Katato K, Hamdy N, Wall N, Al-Katib A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2. Biological Chemistry. 379: 1253-61. PMID 9820586 DOI: 10.1515/Bchm.1998.379.10.1253 |
0.483 |
|
| 1998 |
Liu KZ, Schultz CP, Mohammad RM, Al-Katib AM, Johnston JB, Mantsch HH. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study. Cancer Letters. 127: 185-93. PMID 9619876 DOI: 10.1016/S0304-3835(98)00036-6 |
0.411 |
|
| 1998 |
Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M, Al-Katib A. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Anti-Cancer Drugs. 9: 149-56. PMID 9510501 DOI: 10.1097/00001813-199802000-00006 |
0.444 |
|
| 1998 |
Mohammad RM, Dugan MC, Mohamed AN, Almatchy VP, Flake TM, Dergham ST, Shields AF, Al-Katib AA, Vaitkevicius VK, Sarkar FH. Establishment of a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents Pancreas. 16: 19-25. PMID 9436858 DOI: 10.1097/00006676-199801000-00004 |
0.404 |
|
| 1997 |
Li Y, Mohammad RM, Al-Katib A, Varterasian ML, Chen B. Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors. Leukemia Research. 21: 391-397. PMID 9225065 DOI: 10.1016/S0145-2126(96)00078-1 |
0.399 |
|
| 1997 |
Maki A, Mohammad R, Raza S, Saleh M, Govindaraju KD, Pettit GR, al-Katib A. Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. Anti-Cancer Drugs. 7: 344-50. PMID 8792010 DOI: 10.1097/00001813-199605000-00016 |
0.474 |
|
| 1997 |
König A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines Blood. 90: 4307-4312. DOI: 10.1182/Blood.V90.11.4307.4307_4307_4312 |
0.511 |
|
| 1996 |
Maki A, Mohammad RM, Smith M, Al-Katib A. Role of ubiquitin carboxyl terminal hydrolase in the differentiation of human acute lymphoblastic leukemia cell line, Reh Differentiation. 60: 59-66. PMID 8935929 DOI: 10.1046/J.1432-0436.1996.6010059.X |
0.425 |
|
| 1996 |
Mohammad RM, Raza SA, Maki A, Al-Katib A. Bryostatin 1, A New Anti-tumor Agent: From Bench to Bedside Journal of the Islamic Medical Association of North America. 28. DOI: 10.5915/28-1-6175 |
0.379 |
|
| 1995 |
Mohammad RM, Vistisen K, al-Katib A. Protein study of T and B acute lymphoblastic leukemia cell lines. Electrophoresis. 15: 1218-24. PMID 7859731 DOI: 10.1002/Elps.11501501184 |
0.355 |
|
| 1995 |
Maki A, Diwakaran H, Redman B, al-Asfar S, Pettit GR, Mohammad RM, al-Katib A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs. 6: 392-7. PMID 7670136 DOI: 10.1097/00001813-199506000-00005 |
0.485 |
|
| 1995 |
Mohammad RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B, al-Katib A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leukemia Research. 19: 667-73. PMID 7564478 DOI: 10.1016/0145-2126(95)00037-O |
0.524 |
|
| 1994 |
Mohammad RM, Maki A, Vistisen K, Al‐Katib A. Protein studies of human non-Hodgkin's B-lymphoma: Appraisal by two-dimensional gel electrophoresis Electrophoresis. 15: 1566-1572. PMID 7720694 DOI: 10.1002/Elps.11501501225 |
0.359 |
|
| 1993 |
Mohammad RM, al-Katib A, Pettit GR, Sensenbrenner LL. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leukemia Research. 17: 1-8. PMID 8429674 DOI: 10.1016/0145-2126(93)90134-7 |
0.441 |
|
| 1993 |
al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 33-42. PMID 8399068 DOI: 10.1097/00002371-199307000-00005 |
0.421 |
|
| 1993 |
Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genetics and Cytogenetics. 70: 62-67. PMID 8221615 DOI: 10.1016/0165-4608(93)90132-6 |
0.346 |
|
| 1993 |
Al-Katib A, Mohammad R, Hamdan M, Mohamed AN, Dan M, Smith MR. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model Blood. 81: 3034-3042. DOI: 10.1182/Blood.V81.11.3034.Bloodjournal81113034 |
0.4 |
|
| 1992 |
Mohammad RM, Mohamed AN, Kukuruga M, Smith MR, Al-Katib A. A human B-cell lymphoma line with a de novo multidrug resistance phenotype Cancer. 69: 1468-1474. PMID 1540884 DOI: 10.1002/1097-0142(19920315)69:6<1468::Aid-Cncr2820690626>3.0.Co;2-8 |
0.422 |
|
| 1991 |
Mohammad RM, Clark CR, Maloney TM, Chen BD, Al-Katib A. Expression of a New Cellular Protein by Monocytoid B-Lymphocytes Differentiated from the Acute Lymphoblastic Leukemia Cell Line (REH). Leukemia & Lymphoma. 4: 277-84. PMID 27463048 DOI: 10.3109/10428199109068077 |
0.403 |
|
| 1990 |
al-Katib A, Mohammad RM, Mohamed AN, Pettit GR, Sensenbrenner LL. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematological Oncology. 8: 81-9. PMID 2344999 DOI: 10.1002/Hon.2900080203 |
0.381 |
|
| 1990 |
Patel B, Mohammad RM, Blaustein J, al-Katib A. Induced expression of a monocytoid B lymphocyte antigen phenotype on the REH cell line. American Journal of Hematology. 33: 153-9. PMID 2105637 DOI: 10.1002/Ajh.2830330302 |
0.413 |
|
| 1989 |
Mohamed AN, Mohammad RM, Koop BF, Al-Katib A. Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL). Cancer. 64: 1041-1048. PMID 2527086 DOI: 10.1002/1097-0142(19890901)64:5<1041::Aid-Cncr2820640514>3.0.Co;2-C |
0.43 |
|
| 1989 |
Al‐Katib A, Mohammad RM, Mohamed AN. WSU‐BL: A New Burkitt's Lymphoma Cell Line with Capacity to Differentiate In Vitro Annals of the New York Academy of Sciences. 567: 317-319. DOI: 10.1111/J.1749-6632.1989.Tb16491.X |
0.36 |
|
| Show low-probability matches. |